Research Articles

Research2022-04-19T16:30:19+00:00

LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada

This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata. KIRKLAND, QC, December 4, 2023 – Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance

December 5th, 2023|
Watch Alopecia Areata Research Update 2020

Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.

Go to Top